“Our team at Elevar is very pleased with the results of our pre-NDA meeting with respect to rivoceranib plus camrelizumab as a treatment option for HCC, continuing a collaborative process with the FDA that allows us to maintain our timeline for the upcoming rivoceranib FDA filings in two indications with clearly demonstrated unmet medical need,” said Saeho Chong, chief executive officer of Elevar. “As evidenced by data shared this year, rivoceranib is proving to be efficacious in both monotherapy, for ACC, and in combination with an anti-PD1 inhibitor, for HCC, and we are excited to continue its regulatory development in the months ahead.”
